AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35238894 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemafibrate 0.2 mg twice a day
Number of subjects: 408
Study 35238894 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemafibrate (all doses)
Number of subjects: 408
Study 35238894 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemafibrate
Number of subjects: 408
Study 35238894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 408
Study 33069624 — intervention group
Group type: EXPERIMENTAL
Intervention: Microultrasound (microUS) using the ExactVu system before prostate biopsy
Number of subjects: 320
Study 33069624 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of microUS-targeted and randomized biopsies
Number of subjects: 320
Study 33069624 — intervention group
Group type: EXPERIMENTAL
Intervention: PRI‐MUS score
Number of subjects: 320
Study 33109926 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo groups (informed that the application of an inert cream would reduce pain)
Number of subjects: 166
Study 33109926 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocebo groups (informed that the application of an inert cream would amplify pain)
Number of subjects: 166
Study 33109926 — intervention group
Group type: COMPARATOR
Intervention: No-expectancy control group
Number of subjects: 166
Study 32503395 — intervention group
Group type: EXPERIMENTAL
Intervention: Doctor Office Collaboration Care (DOCC)
Number of subjects: 206
Study 32503395 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication use
Number of subjects: 206
Study 32503395 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication continuity
Number of subjects: 206
Study 32503395 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Number of subjects: 206
Study 36446950 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (180 mg loading dose)
Number of subjects: 169
Study 36446950 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (loading and maintenance doses)
Number of subjects: 169
Study 32251173 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive virtual reality curriculum for clinical assessment training
Number of subjects: 0
Study 34792133 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (5 mg/day)
Number of subjects: 129
Study 34792133 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 33336450 — intervention group
Group type: EXPERIMENTAL
Intervention: Music group
Number of subjects: 107
Study 33336450 — intervention group
Group type: COMPARATOR
Intervention: Non-music group
Number of subjects: 107
Study 33336450 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 107
Study 32730052 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intentions statement only
Number of subjects: 250
Study 32730052 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intentions statement combined with visualization
Number of subjects: 250
Study 32730052 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 250
Study 32730052 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagine in Game
Number of subjects: 250
Study 32730052 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagine in Daily Life
Number of subjects: 250
Study 32730052 — intervention group
Group type: EXPERIMENTAL
Intervention: Statement and Imagine Combined
Number of subjects: 250
Study 34787718 — intervention group
Group type: EXPERIMENTAL
Intervention: Gingival unit graft (GUG)
Number of subjects: 16
Study 34787718 — intervention group
Group type: COMPARATOR
Intervention: Connective tissue graft (SCTG)
Number of subjects: 16
Study 34117965 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth facilitated health coaching intervention (Fitbit Plus)
Number of subjects: 53
Study 34117965 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 53
Study 34117965 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance use
Number of subjects: 53
Study 34117965 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 53
Study 35315592 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenol-rich diet (PR diet)
Number of subjects: 51
Study 35315592 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 51
Study 35176208 — intervention group
Group type: EXPERIMENTAL
Intervention: Drugs with anticholinergic properties (DAPs) prescribed to patients
Number of subjects: 466
Study 35176208 — intervention group
Group type: EXPERIMENTAL
Intervention: High KABS (≥ 3)
Number of subjects: 466
Study 35176208 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific DAPs contributing to total KABS
Number of subjects: 466
Study 35176208 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with high KABS
Number of subjects: 466
Study 35176208 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life in patients with high DAP burden
Number of subjects: 466
Study 33714401 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine
Number of subjects: 0
Study 33714401 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35308520 — intervention group
Group type: EXPERIMENTAL
Intervention: THRIVE
Number of subjects: 100
Study 34139998 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysate sodium concentration of 137 meq/l
Number of subjects: 41
Study 34139998 — intervention group
Group type: COMPARATOR
Intervention: Dialysate sodium concentration of 140 meq/l
Number of subjects: 41
Study 32817713 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocular spherical blur
Number of subjects: 39
Study 32817713 — intervention group
Group type: EXPERIMENTAL
Intervention: Binocular spherical blur
Number of subjects: 39
Study 32817713 — intervention group
Group type: EXPERIMENTAL
Intervention: Binocular astigmatic blur
Number of subjects: 39
Study 32817713 — intervention group
Group type: COMPARATOR
Intervention: Habitual near vision
Number of subjects: 39
Study 35697127 — intervention group
Group type: EXPERIMENTAL
Intervention: Cap-assisted EMR (EMR-C)
Number of subjects: 240
Study 35697127 — intervention group
Group type: COMPARATOR
Intervention: Standard inject and cut EMR (EMR-S)
Number of subjects: 240
Study 34836211 — intervention group
Group type: COMPARATOR
Intervention: TRX suspension training + placebo (TP)
Number of subjects: 40
Study 34836211 — intervention group
Group type: COMPARATOR
Intervention: TRX suspension training + taurine supplementation (TT)
Number of subjects: 40
Study 34836211 — intervention group
Group type: COMPARATOR
Intervention: Taurine supplementation (T)
Number of subjects: 40
Study 34836211 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 40
Study 35565768 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic sleep restriction (CSR, 1:3.3 sleep:wake ratio, n = 9)
Number of subjects: 17
Study 35565768 — intervention group
Group type: COMPARATOR
Intervention: Control (1:2 sleep:wake ratio, n = 8)
Number of subjects: 17
Study 35565768 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Control and CSR)
Number of subjects: 17
Study 34154624 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined model using radiomics features and clinical factors
Number of subjects: 224
Study 34154624 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined model
Number of subjects: 224
Study 34154624 — intervention group
Group type: COMPARATOR
Intervention: Clinical model
Number of subjects: 224
Study 34154624 — intervention group
Group type: COMPARATOR
Intervention: Combined model vs Clinical model
Number of subjects: 224
Study 32017777 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote limb ischemic conditioning (RLIC) plus strength training
Number of subjects: 30
Study 32017777 — intervention group
Group type: COMPARATOR
Intervention: Sham conditioning plus strength training
Number of subjects: 30
Study 34937416 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Cogmed Training (MCT)
Number of subjects: 40
Study 34937416 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (CON)
Number of subjects: 40
Study 32357132 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound (IVUS) use during atherectomy procedures
Number of subjects: 114462
Study 32357132 — intervention group
Group type: EXPERIMENTAL
Intervention: Orbital atherectomy
Number of subjects: 114462
Study 32357132 — intervention group
Group type: COMPARATOR
Intervention: Non-orbital atherectomy
Number of subjects: 114462
Study 616389141 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 x 3 soft capsules of BCSO (0.5 ml each)
Number of subjects: 36
Study 616389141 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 x 3 soft capsules of BCSO (0.5 ml each)
Number of subjects: 36
Study 616389141 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 3 soft capsules of BCSO (0.5 ml each)
Number of subjects: 36
Study 35639451 — intervention group
Group type: EXPERIMENTAL
Intervention: Four online simulation modules (15-20 min each)
Number of subjects: 102
Study 35639451 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=49)
Number of subjects: 102
Study 33977884 — intervention group
Group type: EXPERIMENTAL
Intervention: Syllable-based reading training (24 sessions)
Number of subjects: 101
Study 33977884 — intervention group
Group type: COMPARATOR
Intervention: Waiting control group
Number of subjects: 101
Study 34011396 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided VPS placement
Number of subjects: 0
Study 34011396 — intervention group
Group type: COMPARATOR
Intervention: Stereotactic navigated VPS placement using optical tracking
Number of subjects: 0
Study 32631422 — intervention group
Group type: EXPERIMENTAL
Intervention: BruMeChol™ dietary supplement (one capsule two times a day for 12 weeks)
Number of subjects: 125
Study 32631422 — intervention group
Group type: COMPARATOR
Intervention: Placebo (one capsule two times a day for 12 weeks)
Number of subjects: 125
Study 36062966 — intervention group
Group type: EXPERIMENTAL
Intervention: Somapacitan (0.16 mg/kg/wk)
Number of subjects: 200
Study 36062966 — intervention group
Group type: COMPARATOR
Intervention: Daily GH (Norditropin; 0.034 mg/kg/d)
Number of subjects: 200
Study 33403759 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) infusion during OLDH
Number of subjects: 34
Study 33403759 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 34
Study 32584168 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI
Number of subjects: 0
Study 35726291 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin combined with transnasal ileus catheterization
Number of subjects: 94
Study 35726291 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 94
Study 33567191 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tirbanibulin ointment (1% applied once daily for 5 days)
Number of subjects: 702
Study 33567191 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo) ointment
Number of subjects: 702
Study 32293501 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive screw fixation
Number of subjects: 50
Study 32293501 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 50
Study 35469503 — intervention group
Group type: EXPERIMENTAL
Intervention: Propensity Score Stratification (PSS) in a partially randomized preference design (PRPD)
Number of subjects: 0
Study 35469503 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 to 10 propensity score strata
Number of subjects: 0
Study 34930893 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaze-contingent attention training (n=20)
Number of subjects: 43
Study 34930893 — intervention group
Group type: COMPARATOR
Intervention: Passive viewing of videos (n=23)
Number of subjects: 43
Study 35927745 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 104
Study 35927745 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 104
Study 32910813 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine supplementation (LEU; n=8)
Number of subjects: 16
Study 32910813 — intervention group
Group type: COMPARATOR
Intervention: Control leg (CTL)
Number of subjects: 16
Study 32910813 — intervention group
Group type: COMPARATOR
Intervention: Leucine supplementation (LEU) and placebo (PLA)
Number of subjects: 16
Study 35710695 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrodes placed in the anatomical position
Number of subjects: 203
Study 35710695 — intervention group
Group type: COMPARATOR
Intervention: Electrodes placed at 5‐cm intervals
Number of subjects: 203
Study 32580920 — intervention group
Group type: EXPERIMENTAL
Intervention: BOPT (biologically oriented preparation technique)
Number of subjects: 40
Study 32580920 — intervention group
Group type: COMPARATOR
Intervention: Horizontal chamfer finishing line (control group)
Number of subjects: 40
Study 32580920 — intervention group
Group type: COMPARATOR
Intervention: Both groups (BOPT and control)
Number of subjects: 40
Study 32142566 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin-impregnated bone allograft (BoneAlbumin)
Number of subjects: 24
Study 32142566 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine xenograft (Bio-Oss)
Number of subjects: 24
Study 32142566 — intervention group
Group type: COMPARATOR
Intervention: Control (empty socket)
Number of subjects: 24
Study 33887165 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute circuit training (CT) - 12‐15 repetitions; 65‐70% of 1‐repetition maximum; 3 loops
Number of subjects: 29
Study 35030352 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual simulation intervention
Number of subjects: 88
Study 33392915 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (owners informed the walk would be digitally recorded for evaluation)
Number of subjects: 68
Study 33392915 — intervention group
Group type: COMPARATOR
Intervention: Control group (owners informed the walk would be digitally recorded for archival purposes)
Number of subjects: 68
Study 33392915 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 68
Study 33392915 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 68
Study 32589506 — intervention group
Group type: EXPERIMENTAL
Intervention: Volanesorsen 300 mg SC
Number of subjects: 52
Study 32589506 — intervention group
Group type: EXPERIMENTAL
Intervention: Volanesorsen 300 mg IV
Number of subjects: 52
Study 32589506 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin (positive control)
Number of subjects: 52
Study 32589506 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 36117306 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of COVID-19
Number of subjects: 300
Study 36117306 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 300
Study 36117306 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediation effect of depression
Number of subjects: 300
Study 36117306 — intervention group
Group type: EXPERIMENTAL
Intervention: Social distancing
Number of subjects: 300
Study 35195075 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic balloon dilatation combined with submucosal injection of 40 mg prednisolone
Number of subjects: 64
Study 35195075 — intervention group
Group type: COMPARATOR
Intervention: Conventional endoscopic balloon dilatation
Number of subjects: 64
Study 32380660 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron (1 g ferric carboxymaltose, n = 86)
Number of subjects: 176
Study 32380660 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iron supplementation (10 g iron fumarate, 100 capsules, n = 90)
Number of subjects: 176
Study 36177443 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide (1.25 mg, 3 times/day) with standard care
Number of subjects: 200
Study 36177443 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 200
Study 36177443 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide (1.25 mg, 3 times/day)
Number of subjects: 200
Study 34157996 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum-containing dual-drug chemotherapy combined with Bifico
Number of subjects: 180
Study 34157996 — intervention group
Group type: COMPARATOR
Intervention: Platinum-containing dual-drug chemotherapy
Number of subjects: 180
Study 32091594 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose bivalent HPV vaccine
Number of subjects: 112
Study 32091594 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dose bivalent HPV vaccine
Number of subjects: 112
Study 32091594 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dose bivalent HPV vaccine
Number of subjects: 112
Study 32091594 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated women
Number of subjects: 112
Study 35872530 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib 300 mg twice a day (BD)
Number of subjects: 220
Study 35872530 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib 200 mg three times a day (TDS)
Number of subjects: 220
Study 35872530 — intervention group
Group type: COMPARATOR
Intervention: Placebo BD
Number of subjects: 220
Study 34023024 — intervention group
Group type: EXPERIMENTAL
Intervention: Preclinical randomized controlled trials (pRCT)
Number of subjects: 0
Study 34023024 — intervention group
Group type: COMPARATOR
Intervention: Animal studies
Number of subjects: 0
Study 32840297 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean arterial pressure of 70-80 mmHg during cardiopulmonary bypass (CPB)
Number of subjects: 197
Study 32840297 — intervention group
Group type: COMPARATOR
Intervention: Mean arterial pressure of 40-50 mmHg during cardiopulmonary bypass (CPB)
Number of subjects: 197
Study 35429281 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab (80 mg subcutaneous every 4 weeks)
Number of subjects: 0
Study 35429281 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab (80 mg subcutaneous every 2 weeks)
Number of subjects: 0
Study 35429281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33813611 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD expectancy condition
Number of subjects: 43
Study 33813611 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong a priori beliefs about CBD
Number of subjects: 43
Study 33813611 — intervention group
Group type: COMPARATOR
Intervention: CBD-free hempseed oil
Number of subjects: 43
Study 32967974 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP promotion package
Number of subjects: 1538
Study 36384481 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid-reduced anesthesia (Group MO) with esketamine and alfentanil
Number of subjects: 141
Study 36384481 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid-reduced anesthesia (Group LO) with esketamine and alfentanil
Number of subjects: 141
Study 36384481 — intervention group
Group type: COMPARATOR
Intervention: Traditional opioid-based anesthesia (Group C) with alfentanil
Number of subjects: 141
Study 32283944 — intervention group
Group type: EXPERIMENTAL
Intervention: High education level
Number of subjects: 1442
Study 32283944 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician continuity
Number of subjects: 1442
Study 32283944 — intervention group
Group type: EXPERIMENTAL
Intervention: Written action plan
Number of subjects: 1442
Study 32283944 — intervention group
Group type: EXPERIMENTAL
Intervention: Step 2 maintenance treatment
Number of subjects: 1442
Study 32283944 — intervention group
Group type: EXPERIMENTAL
Intervention: Step 3 treatment
Number of subjects: 1442
Study 32283944 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma/COPD nurse visit (women)
Number of subjects: 1442
Study 32283944 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 1442
Study 32283944 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-morbidities ≥1
Number of subjects: 1442
Study 32283944 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-rated moderate/severe disease
Number of subjects: 1442
Study 35903029 — intervention group
Group type: EXPERIMENTAL
Intervention: FIFA 11+ Kids program
Number of subjects: 780
Study 35903029 — intervention group
Group type: COMPARATOR
Intervention: Usual warm-ups
Number of subjects: 780
Study 34491349 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer cement (GIC)
Number of subjects: 30
Study 34491349 — intervention group
Group type: COMPARATOR
Intervention: Self-adhesive resin cement
Number of subjects: 30
Study 32269148 — intervention group
Group type: EXPERIMENTAL
Intervention: NeuroPAP
Number of subjects: 20
Study 32269148 — intervention group
Group type: COMPARATOR
Intervention: NIPPV
Number of subjects: 20
Study 36110981 — intervention group
Group type: EXPERIMENTAL
Intervention: Sports dance exercises for 20-30 minutes, once a day initially, then twice a day for 180 days of continuous rehabilitation and exercise therapy.
Number of subjects: 81
Study 36110981 — intervention group
Group type: COMPARATOR
Intervention: Routine rehabilitation nursing intervention including dietary nursing intervention and neck traction 3 times a week.
Number of subjects: 81
Study 35056348 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic resection of prostatic utricle (PU)
Number of subjects: 1
Study 35056348 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cystoscopy and laparoscopy for PU resection
Number of subjects: 1
Study 34333138 — intervention group
Group type: EXPERIMENTAL
Intervention: Trust-based intervention at intervention sites promoting relationships between physician-investigators and minority-serving physicians and their minority patients.
Number of subjects: 0
Study 34333138 — intervention group
Group type: EXPERIMENTAL
Intervention: CABANA trial intervention sites
Number of subjects: 0
Study 34333138 — intervention group
Group type: EXPERIMENTAL
Intervention: PACES trial intervention sites
Number of subjects: 0
Study 34333138 — intervention group
Group type: EXPERIMENTAL
Intervention: STEADY‐PD III trial intervention sites
Number of subjects: 0
Study 34333138 — intervention group
Group type: EXPERIMENTAL
Intervention: BMT CTN trial intervention sites
Number of subjects: 0
Study 34333138 — intervention group
Group type: COMPARATOR
Intervention: Control sites implementing only parent trials' recruitment procedures
Number of subjects: 0
Study 32019847 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light (900 lx)
Number of subjects: 27
Study 32019847 — intervention group
Group type: COMPARATOR
Intervention: Standard light (90 lx)
Number of subjects: 27
Study 33233594 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E with total carotenoids
Number of subjects: 1251